Cargando…

Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy

Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte–associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ileana Dumbrava, Ecaterina, Smith, Veronica, Alfattal, Rasha, El-Naggar, Adel K., Penas-Prado, Marta, Tsimberidou, Apostolia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086752/
https://www.ncbi.nlm.nih.gov/pubmed/29787423
http://dx.doi.org/10.1097/CJI.0000000000000224
_version_ 1783346558970888192
author Ileana Dumbrava, Ecaterina
Smith, Veronica
Alfattal, Rasha
El-Naggar, Adel K.
Penas-Prado, Marta
Tsimberidou, Apostolia M.
author_facet Ileana Dumbrava, Ecaterina
Smith, Veronica
Alfattal, Rasha
El-Naggar, Adel K.
Penas-Prado, Marta
Tsimberidou, Apostolia M.
author_sort Ileana Dumbrava, Ecaterina
collection PubMed
description Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte–associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response. The use of immune checkpoint inhibitors exhibit an unique toxicity profile, the immune-related adverse events (irAEs). The most notable immune reactions are noted in skin (rash), gastrointestinal track (colitis, hepatitis, pancreatitis), lung (pneumonitis), heart (myocarditis), and endocrine system (thyroiditis, hypophysitis). We present a patient with metastatic adenoid cystic carcinoma of the left submandibular gland with granulomatous inflammation of the lacrimal glands and axonal neuritis of the cervical and paraspinal nerves following treatment with ipilimumab and radiation therapy.
format Online
Article
Text
id pubmed-6086752
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-60867522018-08-24 Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy Ileana Dumbrava, Ecaterina Smith, Veronica Alfattal, Rasha El-Naggar, Adel K. Penas-Prado, Marta Tsimberidou, Apostolia M. J Immunother Clinical Studies Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte–associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response. The use of immune checkpoint inhibitors exhibit an unique toxicity profile, the immune-related adverse events (irAEs). The most notable immune reactions are noted in skin (rash), gastrointestinal track (colitis, hepatitis, pancreatitis), lung (pneumonitis), heart (myocarditis), and endocrine system (thyroiditis, hypophysitis). We present a patient with metastatic adenoid cystic carcinoma of the left submandibular gland with granulomatous inflammation of the lacrimal glands and axonal neuritis of the cervical and paraspinal nerves following treatment with ipilimumab and radiation therapy. Lippincott Williams & Wilkins 2018-09 2018-08-21 /pmc/articles/PMC6086752/ /pubmed/29787423 http://dx.doi.org/10.1097/CJI.0000000000000224 Text en Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
spellingShingle Clinical Studies
Ileana Dumbrava, Ecaterina
Smith, Veronica
Alfattal, Rasha
El-Naggar, Adel K.
Penas-Prado, Marta
Tsimberidou, Apostolia M.
Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
title Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
title_full Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
title_fullStr Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
title_full_unstemmed Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
title_short Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
title_sort autoimmune granulomatous inflammation of lacrimal glands and axonal neuritis following treatment with ipilimumab and radiation therapy
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086752/
https://www.ncbi.nlm.nih.gov/pubmed/29787423
http://dx.doi.org/10.1097/CJI.0000000000000224
work_keys_str_mv AT ileanadumbravaecaterina autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy
AT smithveronica autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy
AT alfattalrasha autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy
AT elnaggaradelk autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy
AT penaspradomarta autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy
AT tsimberidouapostoliam autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy